Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

This trial is testing a combination of an immunotherapy drug called tislelizumab with chemotherapy (APF regimen) in people who have locally advanced cancers of the head and neck — including the mouth, throat, voice box, and nearby areas. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with squamous cell carcinoma of the head, neck, or throat (stage III–IVb, or stage II–III if HPV-positive) - You have not received chemotherapy, radiation, or other cancer treatments before - You are generally healthy enough to function independently (ECOG 0–1) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have cancer that has spread to distant parts of the body - You have an active autoimmune disease (like lupus, Crohn's, or similar conditions) - You have HIV, uncontrolled hepatitis B or C, or a weakened immune system - You have severe heart problems, active infections, or lung disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.